Voyager Therapeutics (VYGR) Tops Q2 EPS by 23c

Voyager Therapeutics (NASDAQ: VYGR) reported Q2 EPS of ($0.18), $0.23 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $29.58 million versus the consensus estimate of $9.51 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
• Sigma Lithium resumes full operations after signing TAC agreement